Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2019		Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 26,592,845		$ 103,695
Prepaid expenses and other current assets	1,313,931		156,628
Total current assets	27,906,776		260,323
Property and equipment, net	412,735		29,508
Intangible assets, net	1,223,000		41,692
Right-to-use assets	1,347,557		0
Other assets	155,670		12,800
Total assets	31,045,738		344,323
Current liabilities:
Accounts payable	2,665,266		1,412,951
Accrued expenses	446,962		601,889
Restructuring reserve	1,948,596	[1]	0
Operating lease liabilities- short term	477,300		0
Total current liabilities	5,538,124		2,014,840
Noncurrent liability:
Deferred tax liability	157,000		0
Operating lease liabilities- long term	902,972		0
Convertible promissory notes payable	0		30,000
STOCKHOLDERS' EQUITY
Preferred stock, 5,000,000 shares authorized at March 31, 2019 and December 31, 2018, 0 outstanding	0		0
Common stock, $0.00033 par value, 75,000,000 shares authorized at March 31, 2019 and December 31, 2018, 5,172,938 shares and 3,417,187shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively	1,707		1,128
Additional paid-in capital	38,642,411		19,311,529
Accumulated deficit	(14,196,476)		(21,013,174)
Total stockholders' equity	24,447,642		(1,700,517)
Total liabilities and stockholders' equity	$ 31,045,738		$ 344,323

[1] Restructuring reserve relates to the severance costs incurred by Edge Therapeutics prior to the merger transaction and assumed by the Company as part of the purchase accounting, but not yet paid. Restructuring reserve relates to the severance costs incurred by Edge Therapeutics prior to the merger transaction and assumed by the Company as part of the purchase accounting, but not yet paid. For the three months ended March 31, 2019, the Company incurred $121,675 of restructuring expense which is recognized within general and administrative expense.